AEGIRBIO AB ADVANCES FURTHER WITH “ACCESSIBILITY” MILESTONE COMPLETION IN RADx® TECH PROGRAM
Pioneering Accessibility Project for Multiplex Testing Reaches Key Development Milestone
AegirBio AB is thrilled to announce the successful completion of a pivotal milestone within the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx®) Tech program. Building on the award, AegirBio continues to drive innovation with its digital multiplex self-test platform, specifically designed to improve accessibility for individuals with visual, hearing, and dexterity impairments.
The RADx® Tech program, dedicated to expediting diagnostic technology, granted AegirBio an award to advance its accessibility project for multiplex testing. Today's announcement signifies the achievement of one of the four milestones, a critical step in the program which could award up to USD 1.2 million.
During this milestone, AegirBio successfully developed and produced physical models of the platform. Rigorous assessments by intended lay users, particularly individuals with disabilities, were conducted in formative studies. These studies aimed to optimize product design and validate the effectiveness of the platform's accessibility features. AegirBio's commitment to creating a user-friendly, inclusive diagnostic solution is evident through this accomplishment.
Statement by Marco Witteveen, CEO of AegirBio AB:
"As we conclude this milestone, we take pride in sharing the progress of our accessibility project under the RADx® Tech program. The development and validation of physical models, with direct input from our intended users, underscore our dedication to making a meaningful impact. AegirBio envisions a future where innovative diagnostics are not only technologically advanced but also accessible and beneficial to all individuals, including those with disabilities."
AegirBio's RADx® Tech project is partially funded by Federal funds from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health, Department of Health and Human Services, under Contract No. 75N92023D00001.
For additional information, please contact::
Marco Witteveen, CEO, Aegirbio AB
Email: ir@aegirbio.com
About Aegirbio
AegirBio is a Swedish diagnostics company founded in 2019 to offer tests to monitor and optimize the dosage of biological drugs via its unique patented technology platform. In June 2020, AegirBio was listed on the Nasdaq First North Growth Market. The company's ambition is, in addition to bringing innovative diagnostic technology to the market, to make diagnostics more accessible, easier to use and to provide accurate and easily transferable results. For more information, see Aegirbio's website www.aegirbio.com
The company's Certified Adviser is Eminova Fondkomission AB; info@eminova.se